A subgroup analysis from the Phase 3 RASolute 302 trial presented at ESMO reported that daraxonrasib—an investigational targeted RAS inhibitor—extended median survival over chemotherapy across RAS mutation groups in previously treated metastatic pancreatic cancer. The data extend the argument that the benefit may persist despite molecular variability within RAS-driven disease. The analysis evaluated daraxonrasib in combination settings consistent with RASolute 302, focusing on how efficacy translated across patient subgroups defined by RAS alterations. Such stratification matters in pancreatic cancer because clinical responses often vary with tumor genetics and prior treatment exposure. For investors and trial strategists, subgroup-consistent survival signals support the feasibility of further development and combination strategies designed around RAS biology rather than broad histology-only enrollment.